BMC Cancer 2009, 9:372 http://www.biomedcentral.com/1471-2407/9/372 Additional file 3 Table S3. Summary of the adverse events encountered during ISRCTN45828668, classified according to CTCAE V.3.0. Click here for file [http://www.biomedcentral.com/content/supplementary/1471- 2407-9-372-S3.PDF] References 1. Stupp R, Mason WP, Bent MJ van den, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.: Radiother- apy plus concomitant and adjuvant temozolomide for gliob- lastoma. N Engl J Med 2005, 352(10):987-996. 2. Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP, et al.: In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 2004, 10(16):5595-5603. 3. Basu S, Rosenzweig KR, Youmell M, Price BD: The DNA-depend- ent protein kinase participates in the activation of NF kappa B following DNA damage. Biochem Biophys Res Commun 1998, 247(1):79-83. 4. Manna SK, Aggarwal BB: Alpha-melanocyte-stimulating hor- mone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol 1998, 161(6):2873-2880. 5. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville MP: Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 2000, 60(8):1085-1089. 6. Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G, Fuku- shima T: Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. Neurol Med Chir (Tokyo) 2001, 41(4):187-195. 7. Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T: Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 2002, 96(5):909-917. 8. Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN: Analy- sis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 2004, 84(8):941-951. 9. Nagai S, Kurimoto M, Washiyama K, Hirashima Y, Kumanishi T, Endo S: Inhibition of cellular proliferation and induction of apopto- sis by curcumin in human malignant astrocytoma cell lines. J Neurooncol 2005, 74(2):105-111. 10. Tsunoda K, Kitange G, Anda T, Shabani HK, Kaminogo M, Shibata S, Nagata I: Expression of the constitutively activated RelA/NF- kappaB in human astrocytic tumors and the in vitro implica- tion in the regulation of urokinase-type plasminogen activa- tor, migration, and invasion. Brain Tumor Pathol 2005, 22(2):79-87. 11. Piret B, Schoonbroodt S, Piette J: The ATM protein is required for sustained activation of NF-kappaB following DNA dam- age. Oncogene 1999, 18(13):2261-2271. 12. Robe P, Nguyen-Khack MT, Lambert F, Lechanteur C, Jolois O, Ernst- Gengoux P, Rogister B, Bours V: Sulfasalazine unveils a contact- independent HSV-TK/ganciclovir gene therapy bystnader effect in malignant gliomas. International Journal of Oncology 2007, 30(1):283-90. 13. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI: Tumor necrosis factor-alpha- induced protein 3 as a putative regulator of nuclear factor- kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 2006, 24(2):274-287. 14. Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998, 101(5):1163-1174. 15. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H: Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 2005, 25(31):7101-7110. 16. Lo M, Wang YZ, Gout PW: The x(c)-cystine/glutamate anti- porter: a potential target for therapy of cancer and other dis- eases. J Cell Physiol 2008, 215(3):593-602. 17. Rains CP, Noble S, Faulds D: Sulfasalazine. A review of its phar- macological properties and therapeutic efficacy in the treat- ment of rheumatoid arthritis. Drugs 1995, 50(1):137-156. 18. Robe PA, Martin D, Albert A, Deprez M, Chariot A, Bours V: A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. BMC Cancer 2006, 6(1):29. 19. Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kap- lan RS, Bigner DD: GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol 2005, 7(4):425-434. 20. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant gli- oma. J Clin Oncol 1990, 8(7):1277-1280. 21. Gering DNA, Kikinis R, Grimson W, Hata N, Everett P, Jolesz F, Wells W: An Integrated Visualization System for Surgical Planning and Guidance using Image Fusion and Interven- tional Imaging. Int Conf Med Image Comput Comput Assist Interv 1999, 2:11. 22. Vlassenbroeck I, Califice S, Diserens A, Migliavacca E, Straub J, Di Ste- fano I, Moreau F, Hamou M, Renard I, Delorenzi M, et al.: Validation of Real-Time MSP to Determine MGMT Promoter Methyla- tion in Glioma. J Mol Diagn 2008, 10:6. 23. Takahashi H, Ito S, Nagumo K, Kojima S, Umibe T, Hattori T: Sala- zosulfapyridine-induced encephalopathy with symmetrical lesions in the basal ganglia and thalami. Intern Med 2006, 45(15):927-929. 24. Mut SE, Kutlu G, Ucler S, Erdal A, Inan LE: Reversible encephalop- athy due to sulfasalazine. Clin Neuropharmacol 2008, 31(6):368-371. 25. Schoonjans R, Mast A, Abeele G Van den, Dewilde D, Achten E, Van Maele V, Pauwels W: Sulfasalazine-associated encephalopathy in a patient with Crohn's disease. Am J Gastroenterol 1993, 88(10):1759-1763. 26. Sevgi E, Yalcin G, Kansu T, Varli K: Drug induced intracranial hypertension associated with sulphasalazine treatment. Headache 2008, 48(2):296-298. 27. Correale J, Olsson T, Bjork J, Smedegard G, Hojeberg B, Link H: Sul- fasalazine aggravates experimental autoimmune encephalo- myelitis and causes an increase in the number of autoreactive T cells. J Neuroimmunol 1991, 34(2-3):109-120. 28. Mehta D, Malik AB: Signaling mechanisms regulating endothe- lial permeability. Physiol Rev 2006, 86(1):279-367. 29. Hurst RD, Heales SJ, Dobbie MS, Barker JE, Clark JB: Decreased endothelial cell glutathione and increased sensitivity to oxi- dative stress in an in vitro blood-brain barrier model system. Brain Res 1998, 802(1-2):232-240. 30. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003. 31. Li A, Walling J, Kotliarov Y, Center A, Steed ME, Ahn SJ, Rosenblum M, Mikkelsen T, Zenklusen JC, Fine HA: Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 2008, 6(1):21-30. 32. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, Carlin G, Huie MA, Cronstein BN: Methotrexate and sul- fasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of ade- nine nucleotides. J Clin Invest 1998, 101(2):295-300. 33. Rathbone MP, Middlemiss PJ, Kim JK, Gysbers JW, DeForge SP, Smith RW, Hughes DW: Adenosine and its nucleotides stimulate proliferation of chick astrocytes and human astrocytoma cells. Neurosci Res 1992, 13(1):1-17. 34. Olivier S, Robe P, Bours V: Can NF-kappaB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 2006, 72(9):1054-68. Page 7 of 8 (page number not for citation purposes)